ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms

Clinical Proteomics

Volumn 13, Issue 1, 2016, Pages

  Morré, D James ^a   Hostetler, Brandon ^a   Taggart, David J ^a   Morré, Dorothy M ^a   Musk, A W ^b,c,d   Robinson, Bruce W S ^b,c,d   Creaney, Jenette ^b,c  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Asbestos; Early detection; ENOX2; Malignant mesothelioma; ONCOblot tissue of origin cancer test; Serum analysis

Indexed keywords

ASBESTOS; CELL SURFACE PROTEIN; ECTO NICOTINAMIDE ADENINE DINUCLEOTIDE OXIDASE DISULFIDE THIOL EXCHANGER 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASBESTOSIS; BENIGN PLEURA PLAQUE; CLINICAL ARTICLE; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE DURATION; EARLY DIAGNOSIS; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC VARIABILITY; HUMAN; IMMUNOBLOTTING; MALE; MALIGNANT MESOTHELIOMA; ONCOBLOT TISSUE OF ORIGIN CANCER DETECTION TEST; PLEURA PLAQUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84958832516     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/s12014-016-9103-3     Document Type: Article

References (27)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397-408.
2. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591-603.
3. Antman K, Pass H, Schiff P. Benign and malignant mesothelioma. In: DeVita Jr VT, Heliman S, Rosenberg S, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott-Raven; 2001. p. 1943-70.
4. Vongelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplation alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-44.
5. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620-6, 626 e1-3. doi: 10,1016/j.jtcvs.2007.10.054.
6. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovase Surg 1999;117:54-63. discussion 63-5.
7. Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, et al. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidermiol Biomarkers Prev. 2010;19:2238-41.
8. Hostetler B, Weston N, Kim C, Morré DM, Morré DJ. Cancer site-specific isoforms of ENOX2 (tNOX), a cancer-specific cell surface oxidase. Clin Proteomics. 2009;5:46-51. doi: 10.1007/s/2014-008-9016-x.
9. Morré DJ, Morré DM. Early detection: an opportunity for cancer prevention through early interventions. In: Georgakilas AG, editor. Cancer prevention. Rijeka: In Tech; 2012. pp. 389-402.
10. Morré DJ, Morré DM. ECTO-NOX Proteins. New York: Springer; 2013. p. 507.
11. Hanau C, Morré DJ. Morré DM. Cancer prevention trial of a synergistic mixture of green tea concentrate plus Capsicum (Capsol-T) in a random population of subjects ages 40-84. Clin Proteomics. 2014;11:2. doi: 10.1186/1559-0275-11-2.
12. Musk AW, de Klerk NH, Ambrosini GL, Eccles JL, Hansen J, Olsen NJ, et al. Vitamin A and cancer prevention I: observations in workers previously exposed to asbestos at Wittenoom, Western Australia. Int J Cancer. 1998;75:355-61.
13. de Klerk NH, Musk AW, Ambrosini GL, Eccles JL, Hansen J, Olsen N, et al. Vitamin A and cancer prevention II: comparison of the effects of retinol and beta-carotene. Int J Cancer. 1998;75:362-7.
14. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362:1612-6.
15. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest. 2007;132:1239-46.
16. Srivastava S, Gopal-Srivastava R. Biomarkers in cancer screening: a public health perspective. J Nutr. 2002;132:2471S-5S.
17. Greenwald P. A favorable view: progress in cancer prevention and screening. Recent Results Cancer Res. 2007;174:3-17.
18. Neal DE, Donovan JL, Martin RM, Hamdy FC. Screening for prostate cancer remains controversial. Lancet. 2009;2009(374):1482-3. doi: 10.1016/SO140-673(09)61085-0.
19. Shih L-M, Sokoll LJ. Chan DW. In: Diamandis EP, Fritsche HA, Lilia H, Chan DW, Schwartz MK, editors. Ovarian cancer, tumor markers. Washington: AACC Press; 2002. p. 239-52.
20. Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol. 2005;58:308-12.
21. Roggli VL, Sanders IL. Asbestos content of lung tissue and carcinoma of the lung: A clinicopathologic condition and mineral fiber analysis of 234 cases. Ann Occup Hyg. 2000;44:107-17.
22. Lee BW, Wain JC, Kelsey KT, Wiencke JK, Christiani DC. Association of cigarette smoke and asbestosis exposure with location and histology of lung cancer. Am J Respit Crit Care Med. 1998;157:748-55.
23. Robinson BWS, Robinson C, Lake RA. Localized spontaneous regression in mesothelioma - possible immunological mechanism. Lung Cancer. 2001;32:194-201.
24. Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, Pastan I. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res. 2005;11:3814-20.
25. Threitall T, Thompson J, Olsen N. Cancer in Western Australia: incidence and mortality 2003 and mesothelioma 1960-2003. Department of health, statistical series number 74. Perth: 2005.
26. Musk AW, de Klerk NH, Reici A, Ambrosini GL, Fritschi L, Olsen NJ, et al. Mortality of former crocidolite (blue asbestos) miners and millers at Wittenoom. Occup Enviorn Med. 2008;65:541-3.
27. Tang X, Tian Z, Chueh P-J, Chen S, Morré DM, Morré DJ. Alternative splicing as the basis for specific localization of tNOX, a unique hydroquinone (NADH) oxidase to the cancer cell surface. Biochemistry. 2007;46:12337-46.